USPTO Art Unit 1637 Prosecution Statistics

Art Unit Information

Art Unit: 1637
Group: 1630
Tech Center: 1600
Total Cases: 14,725
Last Active: July 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19273982POLYPEPTIDE LINKERS FOR USE IN ENGINEERED MEGANUCLEASESJuly 2025December 2025Allow510NoNo
19214546METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDERMay 2025January 2026Allow820NoNo
19184845COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDApril 2025December 2025Allow810NoNo
19098197METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY CONDITIONS ASSOCIATED WITH INFECTIOUS DISEASEApril 2025January 2026Allow1021NoNo
19086228COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 FAMILY 7 SUBFAMILY A MEMBER 1 (CYP7A1) EXPRESSIONMarch 2025October 2025Allow712YesNo
19084507COMPOSITION AND METHOD FOR INHIBITING ANGIOTENSINOGEN (AGT) PROTEIN EXPRESSIONMarch 2025September 2025Allow610YesNo
19042264PHOSPHATE SENSING MICROBIAL GENE SWITCHJanuary 2025February 2026Allow1221YesNo
19034336COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDJanuary 2025December 2025Allow1120NoNo
19008720C6'-SUBSTITUTED LOCKED NUCLEIC ACID-MODIFIED CAP ANALOG AND USE THEREOFJanuary 2025August 2025Allow711NoNo
19007278COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSIONDecember 2024April 2025Allow400YesNo
18990530CAP COMPOUNDS AND RNAS COMPRISING THE SAMEDecember 2024October 2025Allow1011NoNo
18988719RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of UseDecember 2024August 2025Allow810NoNo
18976078COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1120NoNo
18970086Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative NeoplasmsDecember 2024July 2025Allow700NoNo
18955967DRUGS FOR PREVENTION OR TREATMENT OF SEPSISNovember 2024January 2025Allow200NoNo
18864911SIRNA SPECIFICALLY BINDING TO M2 MACROPHAGE CD206 AND APPLICATION THEREOFNovember 2024June 2025Allow710NoNo
18942162METHOD OF SEQUENCING A NUCLEIC ACID OF INTERESTNovember 2024June 2025Allow720YesNo
18933961COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024November 2025Allow1311NoNo
18934008COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024December 2025Allow1430NoNo
18933819COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024March 2026Allow1630NoNo
18930307METHOD FOR PREVENTING DSRNA BACTERIAL SOLUTIONS FROM BEING DEGRADED BY UVLIGHT AND APPLICATION THEREOF IN CONTROL OF SILVERLEAF WHITEFLIESOctober 2024March 2025Allow410NoNo
18852777MRNA CAP ANALOG AND USES THEREOFSeptember 2024September 2025Allow1110YesNo
18899181Compositions and Methods of Generating Novel amiRNASeptember 2024April 2025Allow701NoNo
18887991COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2024November 2025Allow1411NoNo
18821573COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDAugust 2024January 2026Allow1730YesNo
18820096TREM COMPOSITIONS AND USES THEREOFAugust 2024February 2026Allow1721YesNo
18812463COMPOSITIONS AND METHODS FOR TREATMENT OF BLEEDING DISORDERSAugust 2024February 2026Allow1821NoNo
18800329BEAUVERIA BASSIANA STRAIN WITH HIGH ULTRAVIOLET RADIATION RESISTANCE AS WELL AS DIRECTIONAL MUTAGENESIS METHOD THEREFOR AND USE THEREOFAugust 2024May 2025Allow1011YesNo
18801051SYNTHETIC SELF-AMPLIFYING MRNA MOLECULES WITH SECRETION ANTIGEN AND IMMUNOMODULATORAugust 2024May 2025Allow911YesNo
18793716APPLICATION OF MECHANICAL-FORCE SENSITIVE MACROPHAGE SUBSET IN PANCREATIC CANCER DIAGNOSIS OR PROGNOSIS EVALUATIONAugust 2024June 2025Allow1020NoNo
18790933Novel Retinitis Pigmentosa TreatmentJuly 2024February 2026Allow1841YesNo
18786649Complex for Synthesizing Nucleotide Strand and Method for Synthesizing Nucleotide StrandJuly 2024July 2025Allow1211NoNo
18782965METHOD FOR TREATING C. ACNES BACTERIA-ASSOCIATED DISEASESJuly 2024May 2025Allow1011YesNo
18781699RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USEJuly 2024June 2025Allow1111NoNo
18775784METHOD OF PREPARING SELF-CIRCULARIZED RNAJuly 2024August 2025Allow1311YesNo
18765699METHODS AND COMPOSITIONS FOR MODIFICATION OF PROTOSPACER ADJACENT MOTIF SPECIFICITY OF CAS12AJuly 2024August 2025Allow1330YesNo
18764207SNRNA TARGETING USH2A PRE-MRNA AND APPLICATION THEREOFJuly 2024August 2025Allow1421YesNo
18755160mRNA Capping Enzyme And Methods of Use ThereofJune 2024July 2025Abandon1201NoNo
18752290MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNASJune 2024January 2025Allow701NoNo
18749786ENGINEERED AUTOTROPHIC MICROORGANISMS FOR ISOPRENOID PRODUCTION AND METHODSJune 2024February 2026Abandon2021NoNo
18751048ADVANCED RNA TARGETING (ARNATAR) FOR ANGIOTENSINOGENJune 2024December 2024Allow611YesNo
18677546APPLICATION BASED ON NUCLEOTIDES OF LACTOBACILLUS RHAMNOSUS TO PREPARE A COMPOSITION FOR ANTI-LIPOGENESISMay 2024November 2025Allow1710NoNo
18660600COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASEMay 2024April 2025Allow1111YesNo
18657650NOVEL COMPOUND AND APPLICATION THEREOFMay 2024August 2025Allow1630YesNo
18654906REAGENTS AND METHODS USED IN DEPROTECTION OF 3'-O-AMINO POLYNUCLEOTIDESMay 2024October 2024Allow511YesNo
18650024DELIVERY OF THERAPEUTICS IN VIVO VIA A CRISPR-BASED CASCADE SYSTEMApril 2024December 2025Allow2010NoNo
18646267METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCESApril 2024November 2025Allow1910NoNo
18640905INHIBITORS OF EXPRESSION AND/OR FUNCTIONApril 2024March 2025Allow1110NoNo
18630941METHODS OF IDENTIFYING MULTIPLE EPITOPES IN CELLSApril 2024August 2024Allow400YesNo
18621742RNase InhibitorsMarch 2024October 2025Allow1810NoNo
18617782PHAGE-DERIVED PARTICLES FOR IN SITU DELIVERY OF DNA PAYLOAD INTO C. ACNES POPULATIONMarch 2024July 2025Allow1510NoNo
18594336METHODS FOR MONITORING RESIDUAL DISEASEMarch 2024July 2024Allow410NoNo
18317177OLIGONUCLEOTIDE AND USE THEREOF AGAINST HEPATITIS B VIRUS AND HEPATITIS D VIRUSMarch 2024December 2024Abandon2010NoNo
18588765METHODS OF AMPLIFYING CIRCULAR POLYNUCLEOTIDES IN SITUFebruary 2024August 2024Allow620NoNo
18582279COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDFebruary 2024February 2025Allow1220NoNo
18443300ANTISENSE OLIGONUCLEOTIDES TARGETING SCN2A FOR THE TREATMENT OF SCN1A ENCEPHALOPATHIESFebruary 2024January 2026Allow2310NoNo
18441001COMPOSITIONS AND METHODS FOR INHIBITING TRANSMEMBRANE SERINE PROTEASE 6 (TMPRSS6) EXPRESSIONFebruary 2024November 2025Allow2111NoNo
18436821METHODS FOR EARLY DETECTION OF CANCERFebruary 2024August 2024Allow610NoNo
18427866SIGNAL BOOST CASCADE ASSAYJanuary 2024July 2024Allow530NoNo
18425327MULTIPLE LAMP PRIMER SET, DETECTION METHOD, AND KIT FOR SIMULTANEOUS DETECTION OF MULTIPLE PATHOGENSJanuary 2024August 2024Allow620NoNo
18574729MUTATION SITE OF IDEAL BRITTLE CULM MUTANT ibc IN RICE, CONTROLLING GENE IBC, AND USE THEREOFDecember 2023July 2024Allow600NoNo
18391513Compositions and Methods for Modulating Growth of a Genetically Modified Gut Bacterial CellDecember 2023December 2025Abandon2410NoNo
18538986METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTSDecember 2023August 2024Allow810NoNo
18535485METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTSDecember 2023April 2024Allow410NoNo
18535812SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATIONDecember 2023August 2024Allow910NoNo
18532300MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFDecember 2023April 2025Allow1621YesNo
18567342TREATMENT OF MST1 RELATED DISEASES AND DISORDERSDecember 2023February 2026Abandon2701NoNo
18524856COMPOSITIONS AND METHODS FOR INCREASED PROTEIN PRODUCTION IN BACILLUS LICHENIFORMISNovember 2023June 2025Allow1910YesNo
18523743DIAGNOSTIC KIT FOR METASTASIS AND INVASION OF BREAST CANCER AND USE OF shRNA MOLECULE FOR SILENCING EXPRESSION OF HUMAN LINC01614November 2023March 2025Allow1520NoNo
18523746Compounds and Methods for Reducing LRRK2 ExpressionNovember 2023August 2024Allow900NoNo
18520939DNA Methylation Analysis to Identify Cell TypeNovember 2023June 2024Allow610NoNo
18519727SAFE SEQUENCING SYSTEMNovember 2023April 2024Allow511NoNo
18519295COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2023October 2025Abandon2311NoNo
18520449MRNA TREATMENT NANOPARTICLESNovember 2023July 2025Allow2010NoNo
18516840COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9November 2023December 2025Allow2540YesNo
18514645DIGITAL ANALYTE ANALYSISNovember 2023April 2024Allow511NoNo
18513432ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDESNovember 2023December 2025Abandon2501NoNo
18509899RNase InhibitorsNovember 2023October 2025Allow2310NoNo
18507175METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDERNovember 2023May 2025Abandon1801NoNo
18504952SINGLE-VECTOR TYPE I VECTORSNovember 2023May 2025Allow1810YesNo
18503748MICELLAR NANOPARTICLES AND USES THEREOFNovember 2023March 2026Abandon2821NoNo
18502670COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENENovember 2023September 2025Abandon2301NoNo
18387017cGMP EXOSOME LOADED THERAPEUTICS FOR TREATING SICKLE CELL DISEASENovember 2023January 2025Allow1520YesNo
18498577ADENO-ASSOCIATED VIRUS (AAV) PRODUCER CELL LINESOctober 2023May 2025Allow1821YesNo
18495276PAH-MODULATING COMPOSITIONS AND METHODSOctober 2023August 2025Allow2131YesNo
18383073ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOFOctober 2023November 2025Allow2521NoNo
18492683MODULATORS OF ENaC EXPRESSIONOctober 2023September 2025Abandon2301NoNo
18491071METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTSOctober 2023April 2024Allow610NoNo
18491484ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN BETA-2 MICROGLOBULIN GENEOctober 2023September 2025Abandon2311NoNo
16500637METHOD FOR QUANTITATIVELY CONTROLLING PLASMID COPY NUMBER IN ANTIBIOTIC-FREE PLASMID MAINTENANCE SYSTEMOctober 2023January 2025Allow6011YesNo
18490484DYSTROPHIN GENE EXON DELETION USING ENGINEERED NUCLEASESOctober 2023September 2025Abandon2311NoNo
18488250COMPOSITIONS AND METHODS FOR TREATING SARS-COV-2 INFECTIONOctober 2023September 2025Abandon2310NoNo
18487610SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE)October 2023August 2024Allow1010NoNo
18485615Methods of Detecting Bladder CancerOctober 2023May 2025Allow1920YesNo
18379589METHOD FOR LABELING LIGATION PRODUCTS WITH CELL-SPECIFIC BARCODES IIOctober 2023February 2024Allow400YesNo
18379586METHOD FOR LABELING LIGATION PRODUCTS WITH CELL-SPECIFIC BARCODES IOctober 2023January 2024Allow300NoNo
18484291PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOFOctober 2023May 2025Abandon2001NoNo
18374166COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENESeptember 2023October 2025Allow2511NoNo
18473936ANTISENSE OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTION OR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IASeptember 2023December 2025Abandon2610NoNo
18371373METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGSeptember 2023June 2024Abandon901NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1637.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
201
Examiner Affirmed
139
(69.2%)
Examiner Reversed
62
(30.8%)
Reversal Percentile
42.7%
Lower than average

What This Means

With a 30.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1286
Allowed After Appeal Filing
253
(19.7%)
Not Allowed After Appeal Filing
1033
(80.3%)
Filing Benefit Percentile
5.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1637 - Prosecution Statistics Summary

Executive Summary

Art Unit 1637 is part of Group 1630 in Technology Center 1600. This art unit has examined 14,725 patent applications in our dataset, with an overall allowance rate of 55.6%. Applications typically reach final disposition in approximately 35 months.

Comparative Analysis

Art Unit 1637's allowance rate of 55.6% places it in the 12% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1637 receive an average of 2.10 office actions before reaching final disposition (in the 67% percentile). The median prosecution time is 35 months (in the 29% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.